<DOC>
	<DOCNO>NCT02627053</DOCNO>
	<brief_summary>Anticoagulant therapy generally recommend patient present acute symptomatic splanchnic vein thrombosis , start either low-molecular weight heparin ( LMWH ) unfractionated heparin continue vitamin K antagonists patient . Rivaroxaban approve treatment deep vein thrombosis pulmonary embolism , study assess safety rivaroxaban set splanchnic vein thrombosis . The investigator aim collect prospective information safety rivaroxaban pilot cohort 100 patient acute splanchnic vein thrombosis without liver cirrhosis .</brief_summary>
	<brief_title>Treatment Splanchnic Vein Thrombosis With Rivaroxaban . A Pilot , Prospective Cohort Study</brief_title>
	<detailed_description>Patients splanchnic vein thrombosis increase risk recurrent VTE bleeding . Routine anticoagulation unfractionated heparin low molecular weight heparin follow warfarin recommend setting , limited data available support recommendation 20 % patient receive antithrombotic treatment due fear bleed complication . The pharmacokinetic pharmacodynamic characteristic rivaroxaban make drug ideal alternative therapeutic strategy treatment patient SVT . Thanks oral route administration , short half-life , high bioavailability , predictable dose-response lack effect platelet activity , rivaroxaban could result important alternative LMWH warfarin acute long-term treatment SVT patient . Furthermore , analysis phase III study conduct patient DVT PE show well safety profile rivaroxaban compare standard treatment . This observed benefit safety profile rivaroxaban would extremely relevant treatment patient SVT . In prospective cohort study , patient present acute SVT receive rivaroxaban 15 mg bid 3 week follow rivaroxaban 20 mg od total 3 month . The primary safety efficacy outcome measure 3 month .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Mesenteric Ischemia</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Inclusion criterion : Consecutive patient age 18 year old first episode symptomatic , objectively diagnosed PVT , MVT , spVT sign informed consent . Exclusion criterion : know liver cirrhosis ( biopsy proven clinical , laboratory , image evidence chronic liver disease , within context chronic alcoholism , viral hepatitis , autoimmunity , Wilson 's disease , iron overload ) alanine aminotransferase level three time upper limit normal range higher BuddChiari syndrome previous ongoing vatical bleeding presence portal vein cavernoma time diagnosis anticipate abdominal surgical procedure know bleed diathesis platelet count &lt; 100.000 mm3 creatinine clearance &lt; 30 mL/min ( CockroftGault formula ) life expectancy le 3 month expect inability take oral medication concomitant treatment azole antimycotic human immunodeficiency virus protease inhibitor treatment therapeutic dos LMWH UFH 7 day ongoing treatment VKA pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>